Float Short %

8.56

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

-1.59

EPS Last/This Y

-3.23

EPS This/Next Y

-1.06

Price

63.57

Target Price

81.7

Analyst Recom

1.69

Performance Q

57.13

Upside

-68.5%

Beta

1.24

Ticker: ARWR

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ARWR	67.03	0.40	0.24	38058
2026-01-26	ARWR	66.8	0.40	0.01	38240
2026-01-27	ARWR	66.91	0.40	1.22	38472
2026-01-28	ARWR	65.57	0.40	1.47	38531
2026-01-29	ARWR	69.14	0.40	0.07	38902
2026-01-30	ARWR	69.32	0.40	0.28	39680
2026-02-02	ARWR	73.08	0.40	0.16	39891
2026-02-03	ARWR	72.12	0.39	0.12	40334
2026-02-05	ARWR	64.65	0.40	0.51	43005
2026-02-09	ARWR	62.66	0.39	0.57	44131
2026-02-10	ARWR	62.64	0.39	0.17	44554
2026-02-11	ARWR	61.56	0.39	0.73	44697
2026-02-12	ARWR	62.37	0.39	0.28	44932
2026-02-13	ARWR	63.54	0.39	0.36	45125
2026-02-17	ARWR	63.41	0.39	0.59	45240
2026-02-18	ARWR	64.38	0.39	1.13	45188
2026-02-19	ARWR	63.83	0.39	3.70	45077
2026-02-20	ARWR	63.58	0.39	1.06	45270
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ARWR	67.06	77.3	-303.2	-3.44
2026-01-26	ARWR	66.79	73.6	-309.0	-3.30
2026-01-27	ARWR	66.93	73.6	-310.0	-3.30
2026-01-28	ARWR	65.56	73.6	-306.1	-3.30
2026-01-29	ARWR	69.11	73.6	-319.4	-3.30
2026-01-30	ARWR	69.33	73.6	-310.3	-3.31
2026-02-02	ARWR	73.03	73.6	-319.3	-3.31
2026-02-03	ARWR	72.05	73.6	-307.4	-3.31
2026-02-04	ARWR	68.08	73.6	-	-3.31
2026-02-05	ARWR	64.69	73.6	-	-3.31
2026-02-06	ARWR	64.45	73.6	-	-3.31
2026-02-09	ARWR	62.69	-134.7	-	-3.31
2026-02-10	ARWR	62.91	-135.4	-	-2.93
2026-02-11	ARWR	61.58	-136.0	-	-3.14
2026-02-12	ARWR	62.35	-136.0	-	-3.14
2026-02-13	ARWR	63.83	-137.0	-	-3.29
2026-02-17	ARWR	63.66	-136.7	-	-3.24
2026-02-18	ARWR	64.37	-136.7	-	-3.24
2026-02-19	ARWR	63.88	-136.7	-	-3.24
2026-02-20	ARWR	63.57	-136.7	-	-3.24
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ARWR	-5.39	5.42	7.65
2026-01-26	ARWR	-5.39	4.90	7.65
2026-01-27	ARWR	-5.39	4.90	7.65
2026-01-28	ARWR	-5.39	4.90	8.57
2026-01-29	ARWR	-5.39	4.90	8.57
2026-01-30	ARWR	-5.39	4.90	8.57
2026-02-02	ARWR	-5.24	4.57	8.27
2026-02-03	ARWR	-5.65	4.57	8.27
2026-02-04	ARWR	-5.65	4.57	8.27
2026-02-05	ARWR	-5.50	4.57	8.29
2026-02-06	ARWR	-5.50	4.57	8.29
2026-02-09	ARWR	-5.50	5.75	8.29
2026-02-10	ARWR	-5.50	5.75	8.29
2026-02-11	ARWR	-5.50	5.75	8.56
2026-02-12	ARWR	-5.50	5.75	8.56
2026-02-13	ARWR	-5.50	5.75	8.56
2026-02-17	ARWR	-5.41	6.88	8.56
2026-02-18	ARWR	-5.41	6.88	8.56
2026-02-19	ARWR	-5.41	6.88	8.56
2026-02-20	ARWR	-5.41	6.88	8.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.22

Avg. EPS Est. Current Quarter

-1.01

Avg. EPS Est. Next Quarter

-1.37

Insider Transactions

-5.41

Institutional Transactions

6.88

Beta

1.24

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

63.27

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

32.1

Max Drawdown 5-Year %

-88.9

Target Price

81.7

P/E

41.34

Forward P/E

PEG

P/S

8.16

P/B

15.37

P/Free Cash Flow

27.23

EPS

1.54

Average EPS Est. Cur. Y

-3.24

EPS Next Y. (Est.)

-4.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.54

Relative Volume

0.86

Return on Equity vs Sector %

6.6

Return on Equity vs Industry %

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.2

EBIT Estimation

Arrowhead Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 711

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today

news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance

stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market

stock prices ARWR premarket after hours

ticker ARWR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ARWR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y